SCHEMBL908580

SCHEMBL908580

OC1(N2CCCC2)CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 3/20 0.37
GRIN2A Q12879 3/20 0.37
GRIN2B Q13224 3/20 0.37
PRCP P42785 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
CYP2B6 P20813 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7793042 1.00 GRIN1 (0.37) GRIN1GRIN2AGRIN2BPRCPSIGMAR1
SCHEMBL7035041 1.00 GRIN1 (0.37) GRIN1GRIN2AGRIN2BPRCPSIGMAR1
SCHEMBL5959164 1.00 GRIN1 (0.37) GRIN1GRIN2AGRIN2BPRCPSIGMAR1
SCHEMBL28326008 1.00 GRIN1 (0.37) GRIN1GRIN2AGRIN2BPRCPSIGMAR1
SCHEMBL23673709 0.91 ALDH1A1 (0.33) ALDH1A1
SCHEMBL11124856 0.91 ALDH1A1 (0.33) ALDH1A1
SCHEMBL5154379 0.91 GRIN2D (0.33) GRIN1GRIN2AGRIN2BPRCPSIGMAR1
SCHEMBL11121877 0.91 ALDH1A1 (0.33) ALDH1A1
SCHEMBL7828829 0.88
SCHEMBL5154283 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4208485-A1 PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF ALBEMARLE CORPORATION (US) 2023-07-12 EP disclosed
US-20160008322-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP (CA) 2016-01-14 US disclosed
US-20140314685-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2014-10-23 US disclosed
US-20130171077-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2013-07-04 US disclosed
US-8008342-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2011-08-30 US disclosed
US-20110207730-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-08-25 US disclosed
US-7875611-B2 (+)-trans-[2-(4-morpholinyl)-1-[2-(2-naphthoxy)ethoxy)]; (1R,2R)/(1S,2S)-2-[1,4-dioxa-7-azaspiro[4.4]non-7-yl]-1-(1-naphthenethoxy)cyclohexanecyclohexane; treatment of arrhythmia and the production of analgesia and local anesthesia CARDIOME PHARMA CORP. (CA) 2011-01-25 US disclosed
US-20100056603-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2010-03-04 US disclosed
US-20100029639-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2010-02-04 US disclosed
US-7534790-B2 Ion channel modulating compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2009-05-19 US disclosed
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2005-09-01 US disclosed
US-20050020481-A1 Ion channel modulating compounds and uses thereof BAIN ALLAN I (CA) 2005-01-27 US disclosed
EP-1422217-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2004-05-26 EP disclosed
EP-1087934-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC (CA) 2004-02-25 EP disclosed
EP-0720605-B1 AMINOCYCLOHEXYLESTERS AND USES THEREOF UNIV BRITISH COLUMBIA (CA) 2001-12-19 EP disclosed
EP-1087934-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF Nortran Pharmaceuticals Inc. (CA) 2001-04-04 EP disclosed
US-6174879-B1 BLOCKING SODIUM AND POTASSIUM ION CHANNELS IN VIVO AND IN VITRO; ANTIARRHYTHMIA AGENTS UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-01-16 US disclosed
WO-1999050225-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF NORTRAN PHARMACEUTICALS INC. (CA) 1999-10-07 WO disclosed
EP-0720605-A1 AMINOCYCLOHEXYLESTERS AND USES THEREOF UNIVERSITY OF BRITISH COLUMBIA (CA) 1996-07-10 EP disclosed
WO-1995008544-A1 AMINOCYCLOHEXYLESTERS AND USES THEREOF THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1995-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130171077-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885
US-20110207730-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885
US-20050020481-A1 Ion channel modulating compounds and uses thereof TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885
US-20100056603-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885
US-20160008322-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885
US-20140314685-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885
US-20050192208-A2 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 289/4885GRIN2A 212/4885GRIN2B 251/4885
US-20100029639-A1 ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF TRPV1, TRPA1, KCNN2 GRIN1 254/4885GRIN2A 196/4885GRIN2B 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.